miR-107 Targets NSG1 to Regulate Hypopharyngeal Squamous Cell Carcinoma Progression through ERK Pathway
-
Published:2024-05-29
Issue:11
Volume:25
Page:5961
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Hu Yifan1, He Zhizhen1, Han Baoai1, Lin Zehua1, Zhou Peng1, Li Shuang1, Huang Shuo1, Chen Xiong12
Affiliation:
1. Department of Otolaryngology, Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 2. Sleep Medicine Centre, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
Abstract
Hypopharyngeal squamous cell carcinoma (HSCC) is a kind of malignant tumor with a poor prognosis and low quality of life in the otolaryngology department. It has been found that microRNA (miRNA) plays an important role in the occurrence and development of various tumors. This study found that the expression level of miRNA-107 (miR-107) in HSCC was significantly reduced. Subsequently, we screened out the downstream direct target gene Neuronal Vesicle Trafficking Associated 1 (NSG1) related to miR-107 through bioinformatics analysis and found that the expression of NSG1 was increased in HSCC tissues. Following the overexpression of miR-107 in HSCC cells, it was observed that miR-107 directly suppressed NSG1 expression, leading to increased apoptosis, decreased proliferation, and reduced invasion capabilities of HSCC cells. Subsequent experiments involving the overexpression and knockdown of NSG1 in HSCC cells demonstrated that elevated NSG1 levels enhanced cell proliferation, migration, and invasion, while the opposite effect was observed upon NSG1 knockdown. Further investigations revealed that changes in NSG1 levels in the HSCC cells were accompanied by alterations in ERK signaling pathway proteins, suggesting a potential regulatory role of NSG1 in HSCC cell proliferation, migration, and invasion through the ERK pathway. These findings highlight the significance of miR-107 and NSG1 in hypopharyngeal cancer metastasis, offering promising targets for therapeutic interventions and prognostic evaluations for HSCC.
Funder
Central Universities Zhongnan Hospital of Wuhan University Science, Technology, and Innovation Seed Fund of Zhongnan Hospital of Wuhan University Hubei Provincial Natural Science Foundation
Reference43 articles.
1. Hypopharyngeal cancer: A state of the art review;Garneau;Oral Oncol.,2018 2. Current management strategy of hypopharyngeal carcinoma;Chan;Auris Nasus Larynx,2013 3. Bozec, A., Poissonnet, G., Dassonville, O., and Culié, D. (2023). Current Therapeutic Strategies for Patients with Hypopharyngeal Carcinoma: Oncologic and Functional Outcomes. J. Clin. Med., 12. 4. Liu, J., Pandya, P., and Afshar, S. (2021). Therapeutic Advances in Oncology. Int. J. Mol. Sci., 22. 5. Fan, Y., Li, H., Yu, Z., Dong, W., Cui, X., Ma, J., and Li, S. (2020). Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1. Biosci. Rep., 40.
|
|